Role of Gastric Receptors in Gastrointestinal Disorder


Year : 2024 | Volume : 02 | Issue : 02 | Page : 30-42
    By

    Ambika Nand Jha,

  • Varsha R. Gaikwad,

  1. Assistant Professor, Department of pharmacology, Shri Pandit Baburao Chaughule College of Pharmacy, Maharashtra, India
  2. Assistant Professor, Department of pharmacology, Shri Pandit Baburao Chaughule College of Pharmacy, Maharashtra, India

Abstract

The established and potential roles of CCK1 and CCK2 receptors in gastrointestinal (GI) and metabolic diseases are analyzed, along with findings from human studies involving agonists and antagonists. While there is considerable evidence implicating CCK1R in various diseases such as pancreatic disorders, motility disorders, tumor growth, satiety regulation, and CCK-deficient states, its specific role in these conditions remains ambiguous. Conversely, the role of CCK2R in physiological (e.g., atrophic gastritis) and pathological (e.g., Zollinger-Ellison syndrome) hypergastrinemic states, its effects on gastric mucosa, and its involvement in acid-peptic disorders are well-defined. Recent research also suggests a potential role for CCK2R in various GI malignancies. Current data from human trials investigating CCK2R antagonists are presented, along with their potential therapeutic implications for these conditions. Additionally, the utilization of CCK2 receptors as targets for medical imaging is discussed. Despite being among the earliest discovered gastrointestinal hormones, significant advancements in our understanding of CCK and gastrin signaling have been achieved through structural characterization, pharmacological identification, receptor cloning (CCK1R, CCK2R), and the development of receptor antagonists. Further insights have been gained from studies involving receptor and agonist knockout animals, as well as the characterization of receptor location and gene expression [6]. This review focuses on elucidating the roles of CCK and gastrin and their receptors (CCK1R and CCK2R) in gastrointestinal and metabolic diseases, with particular emphasis on human studies and the potential for utilizing these insights for the treatment of human ailments.

Keywords: Gastrointestinal, cholecystokinin (CCK), CCK1R, CCK2R, Malignancies

[This article belongs to International Journal of Biomedical Innovations and Engineering (ijbie)]

How to cite this article:
Ambika Nand Jha, Varsha R. Gaikwad. Role of Gastric Receptors in Gastrointestinal Disorder. International Journal of Biomedical Innovations and Engineering. 2024; 02(02):30-42.
How to cite this URL:
Ambika Nand Jha, Varsha R. Gaikwad. Role of Gastric Receptors in Gastrointestinal Disorder. International Journal of Biomedical Innovations and Engineering. 2024; 02(02):30-42. Available from: https://journals.stmjournals.com/ijbie/article=2024/view=156990


References

  1. Jensen RT. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol. Toxicol. 2002;91:333–350.
  2. Monstein HJ, Nylander AG, Salehi A, Chen D, Lundquist I, Hakanson R. Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gatrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study. Scand. J. Gastroent. 1996;31:383–390.
  3. Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F, Schmassmann A. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology. 1997;112:1197–1205.
  4. Schmitz F, Goke MN, Otte JM, Schrader H, Reimann B, Kruse ML, Siegel EG, Peters J, Herzig KH, cFolsch UR, Schmidt WE. Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa. Regul. Pept. 2001;102:101–110.
  5. Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology. 2001;121:1380–1390
  6. Rivard N, Rydzewska G, Lods JS, Martinez J, Morisset J. Pancreas growth, tyrosine kinase, PtdIns 3-kinase, and PLD involve high-affinity CCK-receptor occupation. Am. J. Physiol. 1994;266:G62–G70
  7. Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med. Res. Rev. 2003;23:559–605.
  8. Jensen RT. CCKB-gastrin receptor antagonists. Recent advances and potential uses in gastric secretory disorders. Yale J. Biol. Med. 1996;69:245–259..
  9. Liddle RA. Cholecystokinin. In: Walsh JH, Dockray GJ, editors. Gut Peptides. New York: Raven Press; 1994. pp. 175–216.
  10. Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JB, Zach D, Rovati LC, Stalder GA. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet. 1989;2:12–15
  11. Low-Beer TS, Harvey RF, Davies ER, Read AF. Abnormalities of serum cholecystokinin and gallbladder emptying in celiac disease. N. Engl. J. Med. 1975;292:961–963.
  12. Nousia-Arvanitakis S, Fotoulaki M, Tendzidou K, Vassilaki C, Agguridaki C, Karamouzis M. Subclinical exocrine pancreatic dysfunction resulting from decreased cholecystokinin secretion in the presence of intestinal villous atrophy. J Pediatr. Gastroenterol. Nutr. 2006;43:307–312.
  13. Creutzfeldt W. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N. Engl. J. Med. 2001;345:65.
  14. Monstein HJ, Nylander AG, Salehi A, Chen D, Lundquist I, Hakanson R. Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gatrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study. Scand. J. Gastroent. 1996;31:383–390.
  15. Wank SA, Pisegna JR, DeWeerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann. N. Y. Acad. Sci. 1994;713:49–66.
  16. Morisset J, Wong H, Walsh JH, Laine J, Bourassa J. Pancreatic CCK(B) receptors: their potential roles in somatostatin release and delta-cell proliferation. Am. J. Physiol. (Gastrointest. Liver Physiol. 1) 2000;279:G148–G156.
  17. Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology. 2001;121:1380–1390.
  18.  Adler G, Beglinger C, Braun U, Reinshagen M, Koop I, Schafmayer A, Rovati L, Arnold R. Interaction of the cholinergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans. Gastroenterology. 1991;100:537–543.
  19. Beglinger C. Potential role of cholecystokinin in the development of acute pancreatitis. Digestion. 1999;60:61–63.
  20. Tachibana I, Shirohara H, Czako L, Akiyama T, Nakano S, Watanabe N, Hirohata Y, Otsuki M. Role of endogenous cholecystokinin and cholecystokinin-A receptors in the development of acute pancreatitis in rats. Pancreas. 1997;14:113–121
  21. Sato T, Niikawa J, Usui I, Imamura T, Yoshida H, Tanaka S, Mitamura K. Pancreatic regeneration after ethionine-induced acute pancreatitis in rats lacking pancreatic CCK-A receptor gene expression. J Gastroenterol. 2003;38:672–680. 22.
  22. Katz M, Carangelo R, Miller LJ, Gorelick F. Effect of ethanol on cholecystokinin-stimulated zymogen conversion in pancreatic acinar cells. Am. J. Physiol. 1996;270:G171–G175 23.
  23. Satoh A, Gukovskaya AS, Reeve JR, Jr, Shimosegawa T, Pandol SJ. Ethanol sensitizes NF- {kappa}B activation in pancreatic acinar cells through effects on protein kinase C-{epsilon} Am. J Physiol Gastrointest Liver Physiol. 2006;291:G432–G438
  24. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, Landt O, Becker M. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat. Genet. 2000;25:213–216. 25.
  25. Chen JM, Mercier B, Audrezet MP, Ferec C. Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. J Med. Genet. 2000;37:67–69.

 


Regular Issue Subscription Review Article
Volume 02
Issue 02
Received 21/03/2024
Accepted 22/04/2024
Published 20/07/2024


Loading citations…